A Phase I/II, Multi-Center, Open Label Study of Vorinostat Plus Melphalan and Prednisone (ZMP) in Advanced, Refractory Multiple Myeloma Patients.
Phase of Trial: Phase I/II
Latest Information Update: 05 May 2017
At a glance
- Drugs Melphalan (Primary) ; Prednisone (Primary) ; Vorinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 02 May 2017 Planned End Date changed from 1 Mar 2017 to 1 May 2017.
- 09 May 2016 Planned End Date changed from 1 Mar 2014 to 1 Mar 2017.
- 10 Dec 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.